| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
Prostaglandin E2 (PGE2) and glucose-stimulated insulin secretion (GSIS) are inhibited by FKGK18 (1 nM; 1 h) [2]. A 24 hour dose of FKGK18 (0.1–10 nM) reduces β-cell apoptosis [3]. B cell survival and immune cell function are impacted by FKGK18 (0.1–10 μM; 24 hours) [3].
|
|---|---|
| ln Vivo |
Diabetes incidence is lowered by FKGK18 (20 mg/kg; intraperitoneally administered three times a week, beginning on day 10 and continuing until death) [3].
|
| Cell Assay |
Cell viability assay [2]
Cell Types: human islet Tested Concentrations: 1 nM Incubation Duration: 1 hour Experimental Results: Inhibition of GSIS of islets, AA hydrolysis of β-cell membrane and PGE2 production. Penetrated islets and beta cells from islets. Apoptosis analysis [2] Cell Types: INS-1 OE Cell Tested Concentrations: 0.1-10 nM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibition of ER stress-induced β-cell apoptosis. Cell viability assay[3] Cell Types: CD4+ T cells and B cells from 8-12 week old NOD female mice Tested Concentrations: 0.1-10 μM/L Incubation Duration: 24 hrs (hours) Experimental Results: diminished TNF-α production, diminished B cells activity and antibody production. |
| Animal Protocol |
Animal/Disease Models: 10-day-old female NOD mice [3]
Doses: 20 mg/kg Route of Administration: intraperitoneal (ip) injection; 20 mg/kg, 3 times a week; from 10 days to euthanasia Experimental Results: Reduce the incidence of diabetes and maintain better health Good glucose homeostasis. |
| References |
|
| Molecular Formula |
C16H15F3O
|
|---|---|
| Molecular Weight |
280.2902
|
| Exact Mass |
280.107
|
| CAS # |
1071001-09-6
|
| PubChem CID |
25060069
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
382.5±42.0 °C at 760 mmHg
|
| Flash Point |
202.8±19.4 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.528
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
324
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VCWWTQMRNJSJGC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H15F3O/c17-16(18,19)15(20)8-4-1-5-12-9-10-13-6-2-3-7-14(13)11-12/h2-3,6-7,9-11H,1,4-5,8H2
|
| Chemical Name |
1,1,1-trifluoro-6-naphthalen-2-ylhexan-2-one
|
| Synonyms |
FKGK 18; FKGK-18; FKGK18
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~178.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (4.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (4.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (4.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5677 mL | 17.8387 mL | 35.6773 mL | |
| 5 mM | 0.7135 mL | 3.5677 mL | 7.1355 mL | |
| 10 mM | 0.3568 mL | 1.7839 mL | 3.5677 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
